TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10926647

Group type: EXPERIMENTAL
Intervention: Exercise at 0.25LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise at 0.75LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise at LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise at 1.25LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise at 1.75LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise at all intensities
Number of subjects: 10
Study: 8816024

Group type: EXPERIMENTAL
Intervention: Infrapubic (IP) surgical approach
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Penoscrotal (PS) surgical approach
Number of subjects: 86
Study: 1586878

Group type: EXPERIMENTAL
Intervention: Oxymetazoline chloride (5 micrograms or 50 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3514486

Group type: EXPERIMENTAL
Intervention: Indoprofen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 24
Study: 29644957

Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional diabetes (CD) diet
Number of subjects: 16
Study: 27833917

Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse (Group 1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse (Group 2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Two-step self-etch (Group 3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: One-step self-etch (Group 4)
Number of subjects: 32
Study: 26037006

Group type: EXPERIMENTAL
Intervention: Tablet-based application and brochure (N=22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Brochure only (N=23)
Number of subjects: 45
Study: 22540895

Group type: EXPERIMENTAL
Intervention: Screening group (invited for total PSA testing every second year)
Number of subjects: 2353

Group type: COMPARATOR
Intervention: Control group (not invited for screening)
Number of subjects: 2353
Study: 19837746

Group type: EXPERIMENTAL
Intervention: GFR retainers (500 unidirectional glass fibres)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: GFR retainers (1000 unidirectional glass fibres)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Multistranded bonded retainers (gold standard)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no retainers)
Number of subjects: 184
Study: 18593778

Group type: EXPERIMENTAL
Intervention: Xanomeline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16025784

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment (sleep hygiene)
Number of subjects: 30
Study: 11812555

Group type: EXPERIMENTAL
Intervention: Therapeutic nCPAP
Number of subjects: 118

Group type: COMPARATOR
Intervention: Subtherapeutic nCPAP
Number of subjects: 118

Group type: COMPARATOR
Intervention: Difference between Therapeutic and Subtherapeutic nCPAP
Number of subjects: 118
Study: 10524888

Group type: EXPERIMENTAL
Intervention: Bandloop
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard loop
Number of subjects: 53
Study: 7734256

Group type: EXPERIMENTAL
Intervention: Continuous systemic i.v. butorphanol infusion (83.3 micrograms h‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Continuous brachial plexus infusion of butorphanol (83.3 micrograms h‐1)
Number of subjects: 22
Study: 1838818

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study: 6106785

Group type: EXPERIMENTAL
Intervention: Oestrogen supplements
Number of subjects: 37

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Defaulted from oestrogen therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oestrogen dosage
Number of subjects: 37
Study: 29853651

Group type: EXPERIMENTAL
Intervention: 18F‐P3BZA
Number of subjects: 11

Group type: COMPARATOR
Intervention: 18F‐FDG
Number of subjects: 11
Study: 28114795

Group type: EXPERIMENTAL
Intervention: APT198K (xyloglucan plus heat‐killed Lactobacillus reuteri SGL01 and Bifidobacterium brevis SGB01)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lactase dietary supplement
Number of subjects: 46
Study: 25733467

Group type: EXPERIMENTAL
Intervention: Biofortified maize (34 μg zinc/g grain)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fortified maize (60 μg zinc/g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control maize (21 μg zinc/g)
Number of subjects: 60
Study: 23950967

Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention (educational intervention)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 179
Study: 21386767

Group type: EXPERIMENTAL
Intervention: 23-gauge PPV with Densiron-68 and 360° endolaser
Number of subjects: 82

Group type: COMPARATOR
Intervention: 20-gauge PPV with encircling scleral buckling and SF6
Number of subjects: 82
Study: 19647311

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (writing about personal emotional events related to peer problems)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Trivial topics (control group)
Number of subjects: 153
Study: 17277392

Group type: EXPERIMENTAL
Intervention: Strict metabolic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tight blood pressure control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein kinase C inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal steroid injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-platelet agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aldose reductase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advanced glycation end-products inhibitors
Number of subjects: 0
Study: 14717743

Group type: EXPERIMENTAL
Intervention: Trained subjects (T)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overtrained athletes (OA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 23
Study: 11154393

Group type: EXPERIMENTAL
Intervention: Empathy training for nurses
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 9363516

Group type: EXPERIMENTAL
Intervention: Low intensity intervention town
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: High intensity intervention town
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Control town
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Overall study area
Number of subjects: 1620
Study: 8239106

Group type: EXPERIMENTAL
Intervention: Continuous nebulization of 30 mg albuterol over 110 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent nebulization of 30 mg albuterol over 110 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments (Continuous and Intermittent nebulization)
Number of subjects: 0
Study: 3116985

Group type: EXPERIMENTAL
Intervention: Nicardipine 50 mg b.i.d. for 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28866297

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 146
Study: 26818630

Group type: EXPERIMENTAL
Intervention: Checklist for handover
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nonstandardized handover procedure (Control)
Number of subjects: 121
Study: 25511814

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,200 mg/day)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study: 22076415

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 19887830

Group type: EXPERIMENTAL
Intervention: Hemodialysis in patients with diabetic nephropathy (DN)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Hemodialysis in patients with diabetic renal vasculopathy (DV)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Comparison of vascular disease prevalence
Number of subjects: 126
Study: 18440398

Group type: EXPERIMENTAL
Intervention: Patient education programmes (PEP)
Number of subjects: 170
Study: 16319148

Group type: EXPERIMENTAL
Intervention: Tris-acryl gelatin microspheres (TAGM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Spherical polyvinyl alcohol (PVA)
Number of subjects: 36
Study: 12614743

Group type: EXPERIMENTAL
Intervention: High‐dose intravenous methylprednisolone pulse therapy (1 g per day for 3 successive days, repeated 3 times within 3 weeks) followed by 24‐Gy orbital radiotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: High‐dose intravenous methylprednisolone pulse therapy without orbital radiotherapy
Number of subjects: 39
Study: 10702891

Group type: EXPERIMENTAL
Intervention: Cilostazol with aspirin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cilostazol alone
Number of subjects: 12
Study: 8951195

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (2 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study: 1663163

Group type: EXPERIMENTAL
Intervention: lisinopril (10‐40 mg)
Number of subjects: 169

Group type: COMPARATOR
Intervention: enalapril (5‐20 mg)
Number of subjects: 169
Study: 7160424

Group type: EXPERIMENTAL
Intervention: Effervescent tablets (1200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteric coated tablets (650 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium salicylate (1.0 g)
Number of subjects: 0
Study: 31914878

Group type: EXPERIMENTAL
Intervention: Predictive equation for nocturnal hypertension
Number of subjects: 2511

Group type: EXPERIMENTAL
Intervention: Predictive equation for nondipping SBP
Number of subjects: 2511
Study: 31399147

Group type: EXPERIMENTAL
Intervention: FIT039-releasing transdermal patch
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study: 28130749

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (IA) + methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (IA) + IVIG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous azithromycin (IA) + methylprednisolone (group C1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous azithromycin (IA) + IVIG (group C2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous azithromycin (IA) alone (group C)
Number of subjects: 0
Study: 24861845

Group type: EXPERIMENTAL
Intervention: Internal bacterial colonization (specifically Pr. intermedia)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Total bacterial counts
Number of subjects: 26
Study: 24822268

Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg) and low-dose prednisolone (5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21728748

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 40
Study: 19204514

Group type: EXPERIMENTAL
Intervention: Leukoreduced blood transfusions
Number of subjects: 268

Group type: COMPARATOR
Intervention: Regular blood transfusions
Number of subjects: 268
Study: 18088218

Group type: EXPERIMENTAL
Intervention: Parent Training + Classroom Intervention (PT + CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classroom Intervention (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study: 15220255

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 3933

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3933
Study: 11439206

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (ART) - 1.8 Gy twice a day to a dose of 59.4 Gy in 33 fractions over 24 days
Number of subjects: 350

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT) - 2 Gy/day to a dose of 70 Gy in 35 fractions over 49 days
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (ART)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 350
Study: 9731172

Group type: EXPERIMENTAL
Intervention: Planetree Model Hospital Unit
Number of subjects: 0
Study: 7973469

Group type: EXPERIMENTAL
Intervention: Cognitive retraining intervention (15 hours of repeated practice with computer-mediated vigilance tasks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 33
Study: 2500497

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 773801

Group type: EXPERIMENTAL
Intervention: Sulpiride (100 mg i.m. twice daily for 12 days, then 50 mg orally three times daily for 48 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 28606000

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavior therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 64
Study: 27558585

Group type: EXPERIMENTAL
Intervention: Meratrim (400 mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24965754

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) ON
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sacral nerve stimulation (SNS) OFF
Number of subjects: 20
Study: 22631032

Group type: EXPERIMENTAL
Intervention: ASA 81 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ASA 81 mg + esomeprazole 20 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: ASA + esomeprazole
Number of subjects: 29
Study: 19553142

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-20 mg once per day for 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (30 healthy persons)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group I (20 type 2 diabetic patients without nephropathy)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group II (20 type 2 diabetic patients with nephropathy)
Number of subjects: 70
Study: 17643340

Group type: EXPERIMENTAL
Intervention: Unilaterally applied postero‐anterior mobilisation to the left L4/5 zygopophyseal joint
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 16619571

Group type: EXPERIMENTAL
Intervention: 5 mg oral pilocarpine 3 times a day during radiotherapy for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group received pilocarpine only in the second 6 weeks following irradiation
Number of subjects: 66
Study: 12832683

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10781275

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol plus alfentanil 100 ng/ml
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pa and Nb latencies
Number of subjects: 20
Study: 8896009

Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan needle
Number of subjects: 388

Group type: COMPARATOR
Intervention: 27-gauge Quincke needle
Number of subjects: 388
Study: 1683252

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Codeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antigen
Number of subjects: 0
Study: 6355247

Group type: EXPERIMENTAL
Intervention: IPG (immunotherapy with polymerized whole grass)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Caramelized glucose histamine placebo
Number of subjects: 26
Study: 31218545

Group type: EXPERIMENTAL
Intervention: Anti-stigma intervention
Number of subjects: 0
Study: 30583732

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27075909

Group type: EXPERIMENTAL
Intervention: LD + MCT (l‐leucine 1.2 g, cholecalciferol 20 μg, 6 g medium‐chain triglycerides)
Number of subjects: 38

Group type: COMPARATOR
Intervention: LD + LCT (l‐leucine 1.2 g, cholecalciferol 20 μg, 6 g long‐chain triglycerides)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 38
Study: 25204676

Group type: EXPERIMENTAL
Intervention: Intensive nutrition intervention (eight visits with a renal dietitian over the first six months, four visits over the second six months, and three visits over the first six months with an exercise physiologist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (four visits with a renal dietitian over twelve months)
Number of subjects: 0
Study: 22080632

Group type: EXPERIMENTAL
Intervention: C1‐esterase inhibitor infusion (12,000 U) in addition to conventional treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional treatment only (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: C1‐esterase inhibitor infusion
Number of subjects: 61
Study: 19535971

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg/amlodipine 2.5 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/amlodipine 5 mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Atenolol 25 mg alone
Number of subjects: 190

Group type: COMPARATOR
Intervention: Atenolol 50 mg alone
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Atenolol/amlodipine combination
Number of subjects: 190
Study: 17216399

Group type: EXPERIMENTAL
Intervention: Farabloc (F)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: P/F (phase 2)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: F/P (phase 2)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: P/P (phase 2)
Number of subjects: 67
Study: 15872126

Group type: EXPERIMENTAL
Intervention: Capsicum plaster (1 x 1 cm) affixed at the P6 acupoint 30 min before induction of anesthesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg iv given at the end of surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Inactive adhesive plaster (control group)
Number of subjects: 120
Study: 12566894

Group type: EXPERIMENTAL
Intervention: 1-hour paclitaxel infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: 3-hour paclitaxel infusion
Number of subjects: 25
Study: 10847872

Group type: EXPERIMENTAL
Intervention: Mutual visits and feedback by peers
Number of subjects: 90

Group type: COMPARATOR
Intervention: Visits and feedback by non-physician observers
Number of subjects: 90
Study: 8664454

Group type: EXPERIMENTAL
Intervention: 120 mg BN52021 (paf-receptor antagonist) injected twice just before vascular cannulation and before cross-clamp release
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2363546

Group type: EXPERIMENTAL
Intervention: 3 mg.kg‐1 propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 mg.kg‐1 propofol + 1.5 mg.kg‐1 suxamethonium
Number of subjects: 60
Study: 369925

Group type: EXPERIMENTAL
Intervention: oxaprozin 600 mg/day
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: oxaprozin 1200 mg/day
Number of subjects: 212

Group type: COMPARATOR
Intervention: aspirin 3900 mg/day
Number of subjects: 212
Study: 29609032

Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Excision
Number of subjects: 73
Study: 27660329

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 27
Study: 25963394

Group type: COMPARATOR
Intervention: Expressive writing treatments focusing on trauma, sexuality, or daily life (control condition)
Number of subjects: 136
Study: 23445916

Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise (VIB)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Balance training (BAL)
Number of subjects: 68
Study: 20690878

Group type: EXPERIMENTAL
Intervention: Low-load activities (LLA+) post-surgery (n=21)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low-load activities (LLA-) post-surgery (n=17)
Number of subjects: 38
Study: 19742342

Group type: EXPERIMENTAL
Intervention: Polyglycosides of Tripterygium wilfordii (GTW)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 45
Study: 16410202

Group type: EXPERIMENTAL
Intervention: Shared care model (intervention group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 80
Study: 15041597

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (bolus injection of 1.5 mg/kg in 10 min followed by an IV infusion of 1.5 mg/kg/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study: 11765119

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empiric use of GP IIb/IIIa inhibitors
Number of subjects: 0
Study: 8998092

Group type: EXPERIMENTAL
Intervention: i.v. diltiazem
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.v. digoxin
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.v. diltiazem and i.v. digoxin (combination)
Number of subjects: 30
Study: 8343668

Group type: EXPERIMENTAL
Intervention: Preventive home visits by public health nurses (four visits a year over three years)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 580
Study: 3539821

Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg/day for 1 month
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: COMPARATOR
Intervention: Doxycycline and Placebo
Number of subjects: 33